Clinical Trials
109 trialsMK-3475-04A
Merck Sharp & Dohme LLC
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
AbbVie
Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors
Everest Medicines (China) Co.,Ltd.
MK-3475-06B
Merck Sharp & Dohme LLC
RAINFOL-01
Genmab
MK-3475-06C
Merck Sharp & Dohme LLC
MK-5909-003
Merck Sharp & Dohme LLC
MK-3475-G21
Merck Sharp & Dohme LLC
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
Phanes Therapeutics
PRIMAVERA
AstraZeneca
MK-3475-051
Merck Sharp & Dohme LLC
MK-3475-01A
Merck Sharp & Dohme LLC
KRAScendo 170
Hoffmann-La Roche
Keynote B59
GI Innovation, Inc.
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
Aminex Therapeutics, Inc.
OrigAMI-4
Janssen Research & Development, LLC
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer
Cedars-Sinai Medical Center
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
BioNTech SE
Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors
Pyxis Oncology, Inc
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
Tvardi Therapeutics, Incorporated
MK-3475-04D
Merck Sharp & Dohme LLC
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Astellas Pharma Inc
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Verastem, Inc.
Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer
Weill Medical College of Cornell University
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Tango Therapeutics, Inc.
A Study of Tetrathiomolybdate (TM) Plus Capecitabine
Dartmouth-Hitchcock Medical Center
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
BioInvent International AB
Phase I/ II Trial Combining PD-1 Inhibition and Neoadjuvant Proton or Photon Radiation Therapy in Recurrent Head and Neck Squamous Cell Carcinoma
University of Cincinnati
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Bristol-Myers Squibb
Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer
National Institutes of Health Clinical Center (CC)
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
Eikon Therapeutics
FRAPPE
Mayo Clinic
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
ModernaTX, Inc.
MK-3475-06E
Merck Sharp & Dohme LLC
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
Weill Medical College of Cornell University
A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)
National Institutes of Health Clinical Center (CC)
SYNERGY-101
Synthekine
aCCeleR8-001
Shionogi Inc.
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
PMV Pharmaceuticals, Inc
PNeoVCA
Mayo Clinic
A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
D3 Bio (Wuxi) Co., Ltd
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Revolution Medicines, Inc.
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
Pembrolizumab, Ibrutinib and Rituximab in PCNSL
Dana-Farber Cancer Institute
MK-3475-D20
BioInvent International AB
Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer
University of California, San Francisco
EBNK-ST-001
Essen Biotech
KEYNOTE-365
Merck Sharp & Dohme LLC
PREOPANC-5
Amsterdam UMC, location VUmc